In today’s briefing:
- SK Biopharmaceuticals (326030 KS): Starts 2023 on Strong Note; Unveils New Mid to Long-Term Strategy
- InMed Pharmaceuticals, Inc. – Another Super BayMedica Quarter Signaled
SK Biopharmaceuticals (326030 KS): Starts 2023 on Strong Note; Unveils New Mid to Long-Term Strategy
- In 1Q23, SK Biopharmaceuticals Co Ltd (326030 KS) recorded Xcopri U.S. revenue of KRW53.9B, up 70% YoY and 8% QoQ. Xcopri growth is expected to accelerate in US in H2.
- The company’s operating loss narrowed to KRW23B in 1Q23, recording the lowest level excluding the one-off sales, compared with operating loss of KRW45B in 4Q22 and KRW37B in 1Q22.
- The company is looking for Xcopri revenue of KRW300B in 2023. With stable cash generation and expansion into three new modalities, SKBP aims to become a $15B company by 2026.
InMed Pharmaceuticals, Inc. – Another Super BayMedica Quarter Signaled
- BayMedica’s exponential growth momentum continues.
- This morning, InMed Pharmaceuticals (INM) provided a business update on the progress of its BayMedica subsidiary, a leading supplier of rare non- psychoactive cannabinoids to the health & wellness sector.
- In an early disclosure, ahead of a formal release of InMed’s 4QFY23 earnings, expected in September, the company signaled that BayMedica will report a 123% Q/Q increase in revenues to more than $2.3M for the fiscal fourth quarter ended June 30, 2023.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
